Critical period for a teratogenic VLA-4 antagonist: Developmental effects and comparison of embryo drug concentrations of teratogenic and non-teratogenic VLA-4 antagonists.
@article{Crofts2004CriticalPF, title={Critical period for a teratogenic VLA-4 antagonist: Developmental effects and comparison of embryo drug concentrations of teratogenic and non-teratogenic VLA-4 antagonists.}, author={F Crofts and Shashank Rohatagi and Mar{\'i}a Teresa L. Pino and B DeLise and J Zhang and M Nguyen and Pierre Guittin and St{\'e}phane Barbellion and Pascale Brunel and Thomas Hofmann and J. Schmidt and Melisa Wong and Peter M. Lockey and Steven A. Lerman and Robert L Clark}, journal={Birth defects research. Part B, Developmental and reproductive toxicology}, year={2004}, volume={71 2}, pages={ 69-79 } }
BACKGROUND
Integrins such as VLA-4 (Very late antigen 4, integrin alpha4beta1) play key roles in cell-cell interactions that are critical for development. Homozygous null knockouts of the VLA-4 alpha4-subunit or VCAM-1 (VLA-4 cell surface ligand) in mice result in failure of the allantois and chorion to fuse leading to interrupted placentation and cardiac development and embryo lethality. Embryo-fetal studies of three VLA-4 antagonists, IVL745, IVL984, and HMR1031 [Crofts et al., Birth Defects…Â
14 Citations
Different embryo-fetal toxicity effects for three VLA-4 antagonists.
- Medicine, BiologyBirth defects research. Part B, Developmental and reproductive toxicology
- 2004
Dramatic differences in teratogenic potential were observed: IVL745 was not ter atogenic, HMR1031 caused slight embryo-fetal effects at maternally-toxic doses, and IVL984 was a potent teratogen at doses where direct maternal toxicity was limited to abortions in rabbits.
Investigation of the teratogenic potential of VLA-4 antagonist derivatives in rats.
- Medicine, BiologyReproductive toxicology
- 2014
Embryo/fetal development in cynomolgus monkeys exposed to natalizumab, an alpha4 integrin inhibitor.
- Medicine, BiologyBirth defects research. Part B, Developmental and reproductive toxicology
- 2009
Natalizumab had no abortifacient or teratogenic effects, but was associated with changes in fetal hematopoiesis and leukocyte trafficking.
Teratogen update: Malaria in pregnancy and the use of antimalarial drugs in the first trimester
- Medicine, BiologyBirth defects research
- 2020
Limitations in the assessment of the safety of ACTs in the first trimester are a lack of exposures early in gestation, limited postnatal evaluation for cardiovascular malformations, and the pooling of all ACTs for the Assessment of risk.
Thoracic skeletal defects and cardiac malformations: a common epigenetic link?
- BiologyBirth defects research. Part C, Embryo today : reviews
- 2006
A model in which pregnant rats are treated with dimethadione is developed, suggesting a mechanistic link between cardiogenesis and skeletal development, and examines the hypothesis that posttranslational modifications of core histones may be altered by some developmental toxicants.
Very late antigen-4 integrin antagonists
- Medicine, Biology
- 2008
The present review summarizes work establishing natalizumab as an agent for the treatment of multiple sclerosis and Crohn's disease as well as the safety concerns caused by the development of progressive multifocal leukoencephalopathy in three patients during natalIZumab trials.
Maternal PUFAs, Placental Epigenetics, and Their Relevance to Fetal Growth and Brain Development
- Medicine, BiologyReproductive Sciences
- 2022
An optimal level of maternal omega-3 (n-3) PUFAs may protect the placenta’s structural and functional integrity and allow fetal growth by controlling the aberrant placental epigenetic changes.
Maternal n-3 PUFA deficiency alters uterine artery remodeling and placental epigenome in the mice.
- Biology, MedicineThe Journal of nutritional biochemistry
- 2021
Potent in vivo suppression of inflammation by selectively targeting the high affinity conformation of integrin α4β1.
- Biology, ChemistryBiochemical and biophysical research communications
- 2010
Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets
- Biology, MedicineBritish journal of pharmacology
- 2012
There was poor concordance for human pharmacodynamics in genetically deficient mice and for human adverse effects in all three test systems, and no evidence that NHPs have superior predictive value was found.
References
SHOWING 1-10 OF 16 REFERENCES
Different embryo-fetal toxicity effects for three VLA-4 antagonists.
- Medicine, BiologyBirth defects research. Part B, Developmental and reproductive toxicology
- 2004
Dramatic differences in teratogenic potential were observed: IVL745 was not ter atogenic, HMR1031 caused slight embryo-fetal effects at maternally-toxic doses, and IVL984 was a potent teratogen at doses where direct maternal toxicity was limited to abortions in rabbits.
Effects of VLA-4 antagonists in rat whole embryo culture.
- Biology, MedicineTeratology
- 2002
State-selective antagonists of VLA-4 may have an improved embryonic safety profile and therapeutic blood levels in vivo may be several fold lower than those that affect the conceptus, depending on the tissue penetration of the compound and the route of administration.
Targeted disruption of the murine VCAM1 gene: essential role of VCAM-1 in chorioallantoic fusion and placentation.
- Biology, MedicineGenes & development
- 1995
A novel role for VCAM-1 in the formation of the umbilical cord and placenta during development is reported and a role in early placental formation after chorioallantoic fusion was observed.
Selective agonists of retinoic acid receptors: comparative toxicokinetics and embryonic exposure
- Biology, ChemistryArchives of Toxicology
- 2000
Findings suggest that both the embryonic exposure and receptor binding transactivation selectivity are crucial determinants of the teratogenicity of these retinoid ligands.
Single versus multiple dose administration of all-trans-retinoic acid during organogenesis: differential metabolism and transplacental kinetics in rat and rabbit.
- Biology, MedicineToxicology and applied pharmacology
- 1995
The results suggest that multiple administration of a drug such as retinoic acid, which induces its own elimination pathways, results in substantially lowered drug levels in maternal plasma and embryo.
Development of a physiologically based pharmacokinetic model of 2-methoxyethanol and 2-methoxyacetic acid disposition in pregnant rats.
- BiologyToxicology and applied pharmacology
- 2000
The PBPK model for rats as described here is well suited for extrapolation to pregnant women and for assessment of 2-MAA dosimetry under various conditions of possible human exposure to 2-ME.
Adhesive interactions in peri-implantation morphogenesis and placentation.
- BiologyReproductive toxicology
- 1997
Cell adhesion events mediated by alpha 4 integrins are essential in placental and cardiac development.
- BiologyDevelopment
- 1995
The results raise the possibility of abortifacients targeting alpha 4 integrins, and raise serious questions about potential side effects of drugs currently being designed to blockalpha 4 integrin functions in inflammation.
Genetic identification of tissue of origin of cellular populations within the mouse placenta.
- BiologyJournal of embryology and experimental morphology
- 1985
It is shown that cell suspension techniques commonly used to produce 'trophoblast' cell preparations from placenta do not enrich for trophoblast, and, indeed, that collagenase, the preferred dissociation technique for cell viability, produced cell suspensions in which ICM and maternal cells were preferentially dissociated.
The role of integrins in reproduction.
- BiologyProceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine
- 2000
This review will describe the expression of integrins on gametes and during the establishment and development of the placenta, regulatory pathways for controlling expression, and reproductive dysfunction in women related to inappropriate integrin expression in the uterus and/or Placenta.